| Name | Title | Contact Details |
|---|---|---|
Martin Ajayiobe |
Senior Vice President (Infrastructure Systems/Information Security) | Profile |
Archbold Furniture Company has been manufacturing solid wood furniture since 1900. For over 100 years we have worked to provide our customers with high-quality, solid wood products at an exceptional value. In 2010 we partnered with a premier Amish finisher. Since then, all of our finishes are applied by a select group of high-skilled Amish companies. The combination of efficient production methods and custom Amish finishes provides a unique value of high-quality solid wood furniture at affordable prices. Interested in joining our team? Contact HumanResources@archboldfurniture.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.